J

Johnson & Johnson

Makes prescription drugs and medical devices

Global Platform Engineer - Sales CPQ PRO AMP

Full-TimeUpdated on 10/11/2026Deadline 10/17/26
$137k - $236.3k
Expert
Raritan, NJ, USA
Remote

About the job

Requirements
  • At least 10 years of software engineering experience delivering enterprise-scale digital products, platforms, or distributed systems.
  • At least 7 years as a lead architect, principal engineer, platform engineer, or engineering leader accountable for architecture and technical strategy.
  • Demonstrated experience leading a large-scale platform modernization or transformation across multiple teams, products, regions, or business units.
  • Deep expertise in Microsoft Dynamics 365 architecture, extensibility, integration, data models, security, release management, and platform operations.
  • Experience with Microsoft Azure services and integrations across Microsoft 365, including Teams, Outlook, Copilot, and Copilot Studio.
  • Proven experience designing reusable APIs, services, frameworks, SDKs, engineering patterns, or internal developer capabilities rather than only standalone applications.
  • Hands-on understanding of modern engineering practices and tooling, including Git, CI/CD, infrastructure as code, containers, Kubernetes, automated testing, and platform observability.
  • Experience designing or implementing production AI solutions using capabilities such as LLM integration, agent orchestration, RAG, tool calling, context engineering, evaluation, observability, security, and governance.
  • Experience operating in a highly regulated, security-conscious, or otherwise complex enterprise environment.
  • Strong understanding of commercial business processes such as sales, pricing, quoting, contracting, customer engagement, or professional relations.
  • Demonstrated ability to lead through influence across product, engineering, enterprise architecture, security, vendors, and senior stakeholders.
  • Experience providing technical leadership to employees, contractors, delivery partners, or federated engineering teams.
Responsibilities
  • Define and evolve the target architecture and multi-year technical roadmap for the Butterfly CXM platform, with direct accountability for Sales, CPQ, and PR&O.
  • Establish platform boundaries, extension patterns, data flows, integration contracts, identity and access patterns, and non-functional requirements.
  • Ensure architecture decisions support global scale, security, privacy, regulatory requirements, reliability, performance, maintainability, and controlled regional variation.
  • Make technology trade-offs that balance immediate release needs with long-term platform health.
  • Define and lead development of reusable APIs, services, integration patterns, frameworks, SDKs, components, and developer tooling used across CxM product pods.
  • Establish governed patterns for Microsoft Dynamics configuration, customization, integration, data access, testing, release management, and environment management.
  • Create and maintain a catalog of approved platform services, reusable business capabilities, technical patterns, and implementation guidance.
  • Improve developer productivity and delivery quality through automation, standardization, observability, and modern software engineering practices.
  • Define the technical approach for embedding AI and agent-based capabilities into priority commercial workflows across Sales, CPQ, and PR&O.
  • Lead reusable patterns for agent orchestration, tool calling, skills, context management, retrieval-augmented generation, human oversight, evaluation, and lifecycle management.
  • Partner with enterprise AI platform teams to implement governed execution, security controls, observability, discoverability, and production operations.
  • Advance interoperability patterns, including Model Context Protocol and agent-to-agent integration, where appropriate, approved, and valuable.
  • Own CXM platform engineering standards and technical guardrails while aligning with enterprise architecture, cloud, cybersecurity, privacy, data, and AI policies.
  • Provide technical direction and quality oversight across internal engineers, product pods, contractors, systems integrators, and strategic technology partners.
  • Lead architecture reviews, resolve cross-team technical dependencies, and intervene early when delivery choices create platform risk or unnecessary duplication.
  • Coach engineers and technical leads, strengthen engineering capability, and create a culture of accountability, reuse, documentation, and continuous improvement.
  • Communicate architecture decisions, risks, trade-offs, and investment needs clearly to product, business, technology, and executive stakeholders.
Desired Qualifications
  • Experience in MedTech, pharmaceutical, healthcare, or another regulated industry.
  • Experience integrating Microsoft-based business platforms with enterprise services operating across Azure and AWS environments, including API, event-driven, data, identity, security, and observability services.
  • Experience building enterprise agent platforms, internal developer platforms, reusable SDKs, framework libraries, or shared engineering services.
  • Experience designing global platforms that support controlled local or regional variation.
  • Experience managing systems integrators and strategic technology partners in complex delivery environments.
  • Experience leading engineering capability building or organizational transformation.
  • For internal candidates, working knowledge of XENA engineering standards, accelerators, AI-enabled SDLC practices, enterprise architecture standards, deployment frameworks, and CI/CD governance; external candidates should demonstrate experience adopting comparable enterprise engineering frameworks and the ability to rapidly learn J&J standards.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↓ -2%

1 year growth

↓ -2%

2 year growth

↓ -1%
Yahoo Finance
Sep 18th, 2026
J&J stock trades at 28x earnings, but STELARA biosimilar hit distorts valuation

Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.

Yahoo Finance
Sep 14th, 2026
Apollo in talks to acquire J&J's orthopedics unit for $20B

Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.